India is in dialogues with all the vaccine-making companies Modera, Pfizer, Serum, Zydus Cadila, and Bharat Biotech over the progress on clinical trials, safety, immunogenicity, and efficacy, official sources.
After Pfizer and BioNTech , Moderna a U.S. giant drug maker company has announced that the independent,NIH – appointed Data Safety Monitoring Board (DSMB) for the phase – 3 study of mRNA-1273 has shown to have an efficacy of 94.5%.This study is known as the COVE study and enrolled 30,000 participants in the U.S.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stéphane Bancel, Chief Executive Officer of Moderna
According to the sources India is in dialogues with all the vaccine making companies Modera, Pfizer, Serum , Zydus Cadila and Bharat Biotech over the progress on clinical trials, safety , immunogenicity and efficacy .